学会及びパブリケーション

HERIZON-GEA-01: Exploratory Analysis of Response Characteristics and PFS2 in Advanced or Metastatic Gastroesophageal Adenocarcinoma Health-related quality of life with zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive advanced/metastatic gastro-oesophageal adenocarcinoma: Results from HERIZON-GEA-01

Quantitative medicine analyses of zanidatamab dose regimens in patients with HER2-positive locally advanced/metastatic gastro-oesophageal adenocarcinoma RATIONALE-305: Exploratory Analysis of Patient Baseline Characteristics, Efficacy, and Safety in Long-Term Survivors RATIONALE-306: Long-Term Quality-Adjusted Survival Comparison of Tislelizumab + Chemotherapy vs Placebo + Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Advanced Gastric or Gastroesophageal Junction Cancer: A RATIONALE-305 Subgroup Analysis of Patients Treated with Capecitabine Plus Oxaliplatin

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53 Tacabrutideg (BGB-16673), a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a phase 1 CaDAnCe-101 study update

A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: a post hoc analysis of ALPINE A real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States Associations between ECOG performance status and patient-reported outcomes in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: post hoc analysis from the ALPINE Trial BGB-16673, a Bruton tyrosine kinase (BTK) degrader, has low risk of CYP3A-mediated drug-drug interaction (ddi): phase 1 absorption, distribution, metabolism, and excretion and ddi study results BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) Waldenström macroglobulinemia (WM): a phase 1 CaDAnCe-101 study update Bruton tyrosine kinase (BTK) degrader BGB-16673 in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies: Results from the phase 1 CaDAnCe-101 study Clinical outcomes among patients with relapsed/refractory mantle cell lymphoma receiving zanubrutinib or acalabrutinib in real-world practice in the united states Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib in patients with relapsed/refractory mantle cell lymphoma (R/R MCL): results from a Phase 1/1b study Evaluation of PET-CT metrics and pharmacokinetics in adults receiving tislelizumab for relapsed/refractory classical Hodgkin lymphoma: ancillary analyses of LYSA phase 2 TIRHOL study BGB-A317-210 Long-term follow-up for safety and efficacy of Zanubrutinib in elderly (≥80 years) treatment-naïve CLL/SLL patients, including those with del(17p): subgroup analysis from the SEQUOIA trial Patterns of treatment utilization and sequencing across lines of therapy in Waldenström macroglobulinemia (WM): Real-world evidence from the United States Phase 1/2 Study of sonrotoclax (BGB-11417) monotherapy in bruton tyrosine kinase (BTK) inhibitor–pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): a Chinese subpopulation analysis Real-world comparative analysis of treatment discontinuation with covalent bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia (CLL) Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL) Real-world treatment and survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-naïve patients with chronic lymphocytic leukemia in the United States Real-world zanubrutinib treatment patterns in chronic lymphocytic leukemia/small lymphocytic lymphoma among US community oncology patients with prior acalabrutinib therapy Subsequent Therapies and Time to Second Progression-Free Survival Events in Treatment-Naive Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Treated With Zanubrutinib or Bendamustine-Rituximab in SEQUOIA: Long-Term Follow-Up Subsequent therapies and time to second progression-free survival events in chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab in SEQUOIA: long-term follow-up Updated safety and efficacy of all oral sonrotoclax + zanubrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p)/TP53 Zanubrutinib vs Ibrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: Implications for Interpreting Fixed-Duration Outcomes From CLL17

A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: a post hoc analysis of ALPINE A real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States Associations between ECOG performance status and patient-reported outcomes in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: post hoc analysis from the ALPINE Trial BGB-16673 versus idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: the Phase 3 CaDAnCe-302 trial BGB-16673, a Bruton tyrosine kinase (BTK) degrader, has low risk of CYP3A-mediated drug-drug interaction (ddi): phase 1 absorption, distribution, metabolism, and excretion and ddi study results BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) Waldenström macroglobulinemia (WM): a phase 1 CaDAnCe-101 study update BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a phase 1 CaDAnCe-101 study update BRUMIZE: Real-World Zanubrutinib Use and Preliminary Safety in R/R Marginal Zone Lymphoma in Europe Bruton tyrosine kinase (BTK) degrader BGB-16673 in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies: Results from the phase 1 CaDAnCe-101 study Clinical Outcomes among patients with relapsed/refractory mantle cell lymphoma receiving zanubrutinib or acalabrutinib in real-world practice in the United States Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib in patients with relapsed/refractory mantle cell lymphoma (R/R MCL): results from a Phase 1/1b study Efficacy of sonrotoclax versus pirtobrutinib in post–Bruton tyrosine kinase inhibitor relapsed/refractory mantle cell lymphoma: an indirect comparison Evaluation of PET-CT metrics and pharmacokinetics in adults receiving tislelizumab for relapsed/refractory classical Hodgkin lymphoma: ancillary analyses of LYSA phase 2 TIRHOL study BGB-A317-210 Exploring the patient and hematologist preference of treatment characteristics for chronic lymphocytic leukemia (CLL): a qualitative study in Europe First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53 Indirect comparison of zanubrutinib vs acalabrutinib and ibrutinib efficacy in patients with treatment-naive chronic lymphocytic leukemia Long-term follow-up for safety and efficacy of Zanubrutinib in elderly (≥80 years) treatment-naïve CLL/SLL patients, including those with del(17p): subgroup analysis from the SEQUOIA trial Navigating the post–covalent Bruton tyrosine kinase inhibitor landscape in mantle cell lymphoma: real-world insights on treatment patterns, discontinuation, and healthcare resource utilization Number of deaths avoided with use of zanubrutinib versus ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) in Europe Patient-reported outcomes and disease progression in chronic lymphocytic leukemia and small lymphocytic lymphoma: a systematic literature review and gap analysis Patterns of treatment utilization and sequencing across lines of therapy in Waldenström macroglobulinemia (WM): Real-world evidence from the United States Phase 1/2 Study of sonrotoclax (BGB-11417) monotherapy in bruton tyrosine kinase (BTK) inhibitor–pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): a Chinese subpopulation analysis Real-World effectiveness and safety of zanubrutinib in Waldenström macroglobulinemia: results from the Belgian WIZARD study Real-World experience with zanubrutinib in chronic lymphocytic leukaemia – Patient profile, treatment patterns, and safety: preliminary analysis of French ROZALY study Real-world comparative analysis of treatment discontinuation with covalent bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia (CLL) Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL) Real-world intravenous immunoglobulin (IVIG) utilization in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with venetoclax plus obinutuzumab vs zanubrutinib Real-world outcomes among medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKIs) for chronic lymphocytic leukemia (CLL) Real-world treatment and survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-naïve patients with chronic lymphocytic leukemia in the United States Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy Risk of tumor lysis syndrome among patients with chronic lymphocytic leukemia or mantle cell lymphoma treated with venetoclax: a real-world study Sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + acalabrutinib in treatment-naive chronic lymphocytic leukemia: A phase 3 randomized trial design (CELESTIAL-TNCLL-2) Subsequent therapies and time to second progression-free survival events in chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab Treatment burden among patients (pts) aged 75 or older with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) Understanding patients' perspectives and preferences regarding first-line chronic lymphocytic leukemia (CLL) treatment across Europe Updated safety and efficacy of all oral sonrotoclax + zanubrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p)/TP53 Zanubrutinib vs Ibrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: Implications for Interpreting Fixed-Duration Outcomes From CLL17

A Phase 1 Study of BGB-B2033 (GPC3x4-1BB Bispecific Antibody) Monotherapy in Patients With Selected Advanced or Metastatic Solid Tumors: First Disclosure of Clinical Data First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: dose escalation and safety expansion Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: PD-L1 subgroup analysis from HERIZON-GEA-01

A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States Characterization and Management of Gastrointestinal Adverse Events With Zanidatamab + Chemotherapy ± Tislelizumab in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma: Analysis From HERIZON-GEA-01 Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4 – targeting ADC) from pharmacokinetics, efficacy and safety perspectives Exploratory biomarker analysis of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with PD-L1-positive non-small cell lung cancer (NSCLC) in AdvanTIG-105 First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2− breast cancer (BC): A phase 1 safety expansion First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) achieves undetectable minimal residual disease (uMRD) rates of >90%, including in patients with del(17p)/TP53 Navigating the post–covalent Bruton tyrosine kinase inhibitor (cBTKi) landscape in mantle cell lymphoma (MCL): Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization (HCRU) Quality-adjusted survival comparison for tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with peritoneal metastasis (PM): Long-term follow-up from RATIONALE-305 RATIONALE-315: Post hoc analysis of event-free survival by surgically relevant subgroups treated with perioperative tislelizumab and neoadjuvant chemotherapy vs neoadjuvant chemotherapy Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL) Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) Real-world treatment survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naïve patients with chronic lymphocytic leukemia (CLL) in the United States Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2) Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA

Real-World Treatment Utilization, Sequencing Patterns, and Healthcare Resource Utilization in Waldenström Macroglobulinemia (WM) A Novel Bayesian Approach for Assessing Associations Between ECOG Performance Status (ECOG-PS) and Patient-Reported Outcomes (PROs) in Patients With Gastric or Gastroesophageal Junction (GC/GEJC) Adenocarcinoma: Post Hoc Analysis From the RATIONALE-305 Trial A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti-PD-1) in patients with solid tumors A phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) monotherapy in patients with selected advanced or metastatic solid tumors: first disclosure of clinical data A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01 Characterizing Patient Self-Reported Adherence to BTKis and Symptoms in CLL/SLL Using an Electronic Patient-Reported Outcomes (ePRO) Platform Consideration of Adjusted Ideal Body Weight Dosing in BG-C9074 (B7-H4 – targeting ADC) from pharmacokinetics, efficacy and safety perspectives Efficacy of sonrotoclax vs pirtobrutinib in post–Bruton tyrosine kinase inhibitor (BTKi) relapsed/refractory (R/R) mantle cell lymphoma (MCL): an indirect comparison Exploratory biomarker analysis of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with PD-L1-positive non-small cell lung cancer (NSCLC) in AdvanTIG-105 First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2− breast cancer (BC): a phase 1 safety expansion First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: dose escalation and safety expansion First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) achieves undetectable minimal residual disease (uMRD) rates of >90%, including in patients with del(17p)/TP53 Incidence of cardiac-related deaths (CRDs) among patients (pts) aged ≥65 years with B-cell malignancies (BCMs) treated with ibrutinib (ibr) Navigating the post–covalent Bruton tyrosine kinase inhibitor (cBTKi) landscape in mantle cell lymphoma (MCL): real-world insights on treatment patterns, discontinuation, and healthcare resource utilization (HCRU) Quality-Adjusted Survival Comparison for Tislelizumab (TIS) + Chemotherapy (CT) Versus Placebo (PBO) + CT as First-Line (1L) Treatment in Gastric/Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Patients With Peritoneal Metastasis (PM): Long-Term Follow-Up From RATIONALE-305 RATIONALE-315: post hoc analysis of event-free survival by surgically relevant subgroups treated with perioperative tislelizumab and neoadjuvant chemotherapy vs neoadjuvant chemotherapy Real-World Impact of Atrial Fibrillation (AFib) on Cardiovascular (CV) Outcomes and Healthcare Resource Utilization (HCRU) in Patients With Chronic Lymphocytic Leukemia (CLL) Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) Real-world treatment and survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naive patients with chronic lymphocytic leukemia (CLL) in the United States Risk factors for second primary malignancies (SPM) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a real-world study Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2) Subsequent therapies and time to second progression-free survival events (PFS2) in treatment naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01

A phase 2 study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, as monotherapy or in combination with chemotherapy or concurrent chemoradiotherapy in solid tumors BGB-21447, a BCL-2 inhibitor, shows high potential in BCL-2 overexpressing B cell non-Hodgkin lymphomas (NHL) cancers in preclinical studies BGB-21447, a next-generation Bcl-2 inhibitor, demonstrates superior potency and overcomes venetoclax resistance in preclinical models of hematologic malignancies BGB-58067, a brain-penetrative MTA-cooperative PRMT5 inhibitor, demonstrates promising anti-tumor activity and favorable selectivity in tumors with MTAP-deletion Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC) Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumors Sonrotoclax (BGB-11417), a selective BCL-2 inhibitor, demonstrates better efficacy than venetoclax and lisaftoclax (APG-2575) in hematological cancer cells, xenografts, and human bloods

A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, as monotherapy or in combination with chemotherapy or concurrent chemoradiotherapy in solid tumors A phase 2 study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) BGB-21447, a next generation Bcl-2 inhibitor, shows high potential in Bcl-2 overexpressing non-Hodgkin lymphomas (NHL) cancers in preclinical studies BGB-21447, a next-generation BCL-2 inhibitor, demonstrates superior potency to venetoclax and overcomes diverse BCL-2 mutations in preclinical models of hematologic malignancies BGB-58067, a brain-penetrative MTA-cooperative PRMT5 inhibitor, demonstrates promising anti-tumor activities and favorable selectivity in tumors with MTAP-deletion Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC) Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumors Sonrotoclax (BGB-11417), a selective Bcl-2 inhibitor, demonstrates better efficacy than venetoclax (Ven) and lisaftoclax (APG-2575) in hematological cancer cells, xenografts, and human bloods

Electronic Patient-Reported Cardiovascular-Related and Clinically Relevant Symptoms in Patients Diagnosed With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Treated With a Second-Generation Bruton Tyrosine Kinase Inhibitor Real-World Chronic Lymphocytic Leukemia–Specific Biomarker Testing Patterns and Frontline Treatment Patterns in Community Oncology Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: an Electronic Health Record Study Switching to Zanubrutinib in Patients Diagnosed With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Previously Treated With Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting Treatment Patterns and Healthcare Resource Utilization in Advanced Esophageal Cancer Across Racial and Ethnic Groups in the Immunotherapy Era: A Retrospective Claims Data Analysis in the United States Treatment Patterns and Outcomes Among Patients Treated With Next-Generation Covalent Bruton Tyrosine Kinase Inhibitors (cBTKi) in Chronic Lymphocytic Leukemia (CLL) at the University of California San Francisco Health (UCSF) System

Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in community oncology patients with CLL/small lymphocytic lymphoma (SLL): an electronic health record study

Zanubrutinib + Obinutuzumab Vs Obinutuzumab in Relapsed/Refractory Follicular Lymphoma: Final Analysis of ROSEWOOD

Number Needed to Treat to Avoid Progression or Death in Relapsed/Refractory Chronic Lymphocytic Leukemia Patient Preferences and Factors Affecting Patient Treatment Decisions for Chronic Lymphocytic Leukemia in Japan

JSMO 2026 Abstract: ALPINE LTE1 Zanu Patients